Clinical Trial

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

Name: A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） — clinical trial record (NCT07399444)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LB2505-0001

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07399444
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Nanjing Legend Biotech Co.
Conditions	Multiple Myeloma (MM)
Enrollment	38 participants
Start Date	2026-01-10
Primary Completion	2028-07-10 (estimated)
Study Completion	2030-05-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-10